Peptides Explained

Proposed tissue repair

BPC-157

A lab-made peptide, mostly studied in rats by one Zagreb group. Nobody knows what it does in people.

Not an authorised medicine

At a glance

Is it an approved medicine?
No Not approved as a medicine in the EU, the UK or the US.
Has it been tested in people?
Very little Only reports about a few patients, not proper trials.
Is it allowed in sport?
No Banned in sport at all times. Anti-doping list (WADA), section S0
What is the biggest risk?
Unknown effects in people. Vials may hold germs or the wrong substance. More about the risks

Status checked on . The details and sources are further down this page.

Stop and get help if you notice

  • Hot, red, swollen injection site, or fever1
  • Hives, swollen face or throat, hard to breathe1
  • New lump, unexplained bleeding, or one swollen leg1,11

If it is severe, call your local emergency number.

All warning signs, further down this page Warning signs for any peptide

The 30-second version

About 9 minutes for the short version; 44 with every detail open.

  • BPC-157 is a lab-made chain of 15 amino acids. No country has approved it as a medicine.
  • Most research was in rats. Nearly nine in ten lab papers come from one group in Zagreb, Croatia.
  • Only four very small reports on people have been published in full. None had a comparison group.
  • Nobody knows if it works in people or how safe it is. It is banned in sport.
  • In July 2026, US advisers backed letting pharmacies make it. It was only advice; the law is unchanged.
Class
Proposed tissue repair
Main research source
One Zagreb group: about 140 of 160 lab papers
Routes with human results
Enema, and injections into joint, bladder wall, vein or gum
Half-life in animals
15 min in rats, 5 in dogs, into a vein
Trials under way
One placebo-controlled trial recruiting (hamstring strain, China)
Status in the EU
Not authorised
Tested in people
Very little

Label facts, not dosing advice. Sources are in the sections below.

Last reviewed
The main building of the School of Medicine in Zagreb: a glass front that reflects an older building, above a paved square with benches and a small statue.
The main building of the medical school in Zagreb, Croatia. Photo: Suradnik13 (Wikimedia Commons) CC BY-SA 3.0 Image details

Each section starts with the short answer. The rest is folded under “In detail”.

Evidence profile

Four separate questions. Not a score.

Human clinical evidence How far has it been tested in people?
Case reports only
Preclinical volume How much laboratory and animal research exists?
Extensive
Source independence How many independent groups produced it?
One group dominates
Safety characterisation How well do we know the harms in humans?
Uncharacterised
In detail Why these grades: the reason for each step
Human clinical evidence
Case reports. The only published human data are four small reports without a comparison group: three led by the same US clinician (16, 12 and 2 people), and one on 3 dental patients who received BPC-157 mixed with four other drugs. A randomised phase 2 trial in 53 people with ulcerative colitis exists only as a 2005 conference abstract, and a placebo-controlled phase 1 study in 32 healthy men only as earlier abstracts. Neither was published in full, so under our rubric they do not count as published phase 1 or phase 2 trials.
Preclinical volume
Extensive. By our count on 20 October 2026, PubMed holds about 160 primary laboratory and animal studies of BPC-157, far above the threshold of 50.
Source independence
Single group dominant. Authors from one group at the University of Zagreb appear on about 140 of roughly 160 primary experimental papers (about 85%). About 20 come from groups outside Zagreb, few of which repeat the group's experiments directly. The only independent test of the rat Achilles-tendon claim (2026) found no statistically significant effect on tendon strength or overall tissue scores, though one collagen measure did differ.
Safety characterisation
Uncharacterised. The published human studies are tiny and short, and most do not say how safety was monitored; the FDA concluded in 2026 that the clinical safety information is insufficient to characterise the safety profile. The animal toxicology comes from one laboratory and lasts 28 days at most.

We never add these up. A compound can have a large animal literature from one laboratory and no human data at all — that is a specific situation, and a single number would hide it. How we grade evidence

In detail The molecule: amino-acid sequence and technical details
Amino-acid sequence15 amino acids

H–Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val–OH

Read from the N-terminus (start) to the C-terminus (end).

Full name
Body Protection Compound-157
Also called
BPC 157, PL 14736, PL-10, PLD-116, bepecin
Class
Proposed tissue repair
Body systems
Muscles, tendons, bones, Gut
Formula
C62H98N16O22
Molecular mass
1,419.5 Da

What it actually is

What is BPC-157?

A lab-made chain of 15 amino acids. No country has approved it as a medicine.
BPC-157 is made in a lab, has no official medicine name, and is approved nowhere. What is known about the substance sold under this name, checked on 20 October 2026.
BPC-157
Made in a lab?Yes By chemical synthesis, one amino acid at a time.1,2
A substance the body makes?Unknown A Zagreb group reported it as part of a protein in stomach juice. Its sequence looks like no known gut peptide.3,4
An official medicine name?No “BPC-157” is only a common name.1
One substance under that name?No Different substances are sold under it, such as a free base or an acetate salt.1
Approved as a medicine anywhere?No The FDA found no approved product in any country.1

BPC-157 is promoted online for tendon, ligament, muscle and gut problems, with record search interest in 2024.1,5 That popularity does not rest on human trials, because there are almost none.

In detail The molecule, and how it is made

BPC-157 is a synthetic peptide: a chain of 15 amino acids, Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, with ordinary free ends. Its formula is C62H98N16O22 and its mass is 1419.5 Da.6 Early laboratory work reported that it resists breakdown in gastric juice.1 Four of its amino acids are proline, and proline-rich stretches resist many digestive enzymes, which may explain that stability . In blood, by contrast, it is broken down within minutes.2

How it is made

It is made by solid-phase peptide synthesis: amino acids are added one at a time to a chain anchored on resin beads, then the chain is cut free and purified. Each step can leave shortened or wrongly built chains, solvents and reagents behind. Commercial material comes as a free base or as an acetate salt, which the FDA treats as different substances; PubChem also lists a trifluoroacetate salt.1,6

In detail Where the name comes from, and who developed it

“BPC” stands for Body Protection Compound. In 1993 a group at the University of Zagreb described a protein of about 40,000 daltons isolated from human gastric juice. They named it BPC and described BPC-157 as a 15-amino-acid fragment “thought to be essential for its activity”.3,1 That origin rests on the group’s own reports. The FDA describes the peptide as “reported to be” such a fragment, and an independent review notes that its sequence resembles no known gut peptide.1,4 The peptide used in research is made by chemical synthesis.1,2

In the 1990s and 2000s the Croatian company PLIVA developed it under the codes PL 14736 and PLD-116; the names PL-10 and bepecin also appear in databases.7,8,9 It has no official non-proprietary name. The FDA notes that “BPC-157” is only a common name, and that different chemical substances are sold under it.1

Proposed mechanism

How does it work?

Nobody knows how it works, or whether it does anything in people.

The FDA’s 2026 review says its molecular targets “have not been identified and its mechanisms of action remain poorly understood”.1 What exists is a set of observations in cells and rats that no single study connects, and none was made in a person.

The short animation walks along the proposed chain and shows where each step was seen.

Animation · 30 seconds The chain proposed for BPC-157, and where each step was seen

Your device asks for less motion, so this animation does not play. The picture shows the end result and the list explains every step.

  1. Nobody knows where BPC-157 first acts on a cell. One 2026 study proposed a partner, not yet repeated.

    Hypothesised

  2. In a dish, it raised signals in vessel cells, mostly in one lab. Human artery pieces relaxed too.

    In cells

  3. Tendon cells in a dish moved more and survived stress better. But they did not divide faster.

    In cells

  4. In injured rat tissue, more small blood vessels grew. Most of these studies come from one Zagreb group.

    In animals

  5. Rats healed faster in Zagreb studies. One tendon test by another lab found no clear strength gain.

    In animals

  6. In people, none of these steps has been shown. No controlled trial has been published in full.

    Hypothesised

In short: The chain starts with a gap: no target for BPC-157 is established. In a dish it raised vessel signals and helped tendon cells move. In rats, more small vessels grew and tissue healed faster, mostly in one group's studies; one outside tendon test found no clear gain. None of this has been shown in people.

Lines: long dashes = shown in animals long dashes = shown in cells in the lab short dashes = an idea, not yet shown

Based on: FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 20261; Zhang et al. (2026)10; Hsieh et al. (2017)11; Hsieh et al. (2020)12; Yildirim et al. (2026)13; Chang et al. (2011)14; Brcic et al. (2009)15; Staresinic et al. (2003)8; Biçer et al. (2026)16; Poolton et al. (2026)17

In detail The proposed chain in one table, with its sources
Some steps were seen in the lab or in rats. None has been shown in people. The proposed chain, step by step, and where each step was seen.
In the lab or in ratsIn people
Binds one known target?Unknown None is established. One 2026 cell study proposes a protein called FBXO22; it has not been repeated.1,10Unknown Not studied in people.
Switches on blood-vessel signals?Yes In cells, mostly in one lab in Taiwan. Pieces of human artery in a dish relaxed, mostly through nitric oxide.11,12,13Unknown Not measured in a living person.
Cells move faster and survive stress?Yes In rat tendon cells, in the same lab in Taiwan.14Unknown Not measured in people.
More blood vessels in healing tissue?Yes In injured rats, mostly reported by the Zagreb group.15,11Unknown Not measured in people.
Faster healing?Yes In many Zagreb rat studies. One independent tendon test found no significant gain in strength, though one collagen measure improved.8,16Unknown No controlled trial has been published in full.17
In detail Step by step: the proposed chain and what each step rests on
The proposed causal chain, step by step

Each step is labelled with how well the link from the previous step is established.

  1. Step 1 Binding Hypothesised

    No receptor has been identified

    Most drugs act by binding a specific target. For BPC-157 none is established; the FDA's 2026 review states its molecular targets have not been identified. One 2026 cell study proposes that it binds an intracellular protein (FBXO22), but this has not been repeated.

  2. Step 2 Signal inside the cell In cells

    Blood-vessel cells: VEGFR2 and nitric oxide

    In cultured human blood-vessel cells, BPC-157 increased the amount of the receptor VEGFR2 and switched on the VEGFR2–Akt–eNOS pathway that makes nitric oxide. Shown by one laboratory in Taiwan; a Turkish group later found that it relaxed pieces of human artery mainly through nitric oxide.

  3. Step 3 Signal inside the cell In cells

    Tendon cells: FAK–paxillin and growth hormone receptor

    In rat tendon fibroblasts it increased activation of focal adhesion kinase (FAK) and paxillin, and raised the number of growth hormone receptors. Same Taiwanese laboratory. Separately, the developer's own lab reported that, in a human gut-cell line, it switched on the repair gene EGR-1 faster than a known growth factor.

  4. Step 4 Cell response In cells

    Cells move, survive stress and form tubes

    Treated fibroblasts migrated and spread faster and survived oxidative stress better; endothelial cells formed more vessel-like tubes. BPC-157 alone did not make tendon cells divide faster, although the Xi'an laboratory reported faster growth of endothelial cells. The Zagreb group found no direct effect on vessel growth in culture.

  5. Step 5 Tissue response In animals

    More vessels and better-organised collagen in healing tissue

    In injured rats, treated tissue showed more blood vessels and more organised collagen. Mostly reported by the Zagreb group; the Taiwanese lab saw faster blood-flow recovery in ischaemic rat legs.

  6. Step 6 Effect on the body In animals

    Faster healing in rodent injury models

    Tendon, ligament, muscle and gut injuries healed faster in rats in many Zagreb studies. One independent tendon study (32 rats) saw stronger tendons and better tissue scores that did not reach statistical significance; one collagen measure did.

  7. Step 7 Effect on the body Hypothesised

    Benefit for injured people: not shown

    No controlled human trial has been published in full. Whether any step above happens in people, at which amounts, and whether it improves recovery is unknown.

Step 1: the missing receptor

A drug normally starts by binding one specific target, such as a receptor or an enzyme. That binding is what makes its effects predictable and dose-dependent. For BPC-157 no target is established.1 In 2026 the laboratory in Xi’an, China, that also ran the animal toxicology reported that, in cultured human endothelial cells (the cells that line blood vessels), BPC-157 binds the protein FBXO22 and so protects the transcription factor BACH1 from breakdown, increasing cell growth and tube formation .10 It is the first specific partner proposed, from one laboratory, and not yet repeated.

There is also a timing puzzle. In rats and dogs, intact BPC-157 leaves the blood within minutes, cut into fragments and then amino acids,2 yet animal studies report effects that build up over days. Why is unknown.

Steps 2 to 4: signals and cell behaviour

Most signalling data come from one laboratory at Chang Gung University in Taiwan, which has no link to Zagreb:

  • In human endothelial cells, BPC-157 raised levels of VEGFR2, the main receptor for the vessel-growth signal VEGF, and activated the VEGFR2–Akt–eNOS pathway .11
  • In isolated rat aorta, it relaxed the vessel through nitric oxide made by the lining cells; blocking nitric oxide synthesis with L-NAME inhibited the effect .12 In 2026 a group in Ankara, Turkey, tested this in human tissue: in rings of chest artery left over from heart-bypass surgery in 12 men, BPC-157 relaxed the artery mostly through the vessel lining and nitric oxide, and L-NAME weakened the effect . The authors note that their concentrations were far higher than the blood levels measured in rats.13
  • In rat tendon fibroblasts, it increased activation of focal adhesion kinase (FAK) and paxillin, proteins that let a cell grip its surroundings and crawl, and the cells migrated faster and survived oxidative stress better . They did not divide faster.14
  • In the same cells, it raised the number of growth hormone receptors, so added growth hormone made the cells multiply more .18

The developer’s laboratory reported that in a human gut-cell line PL 14736 switched on EGR-1, a gene cells turn on within minutes of injury, faster than PDGF-BB, the growth factor in the wound gel becaplermin .9

The laboratories do not always agree. The Taiwanese group saw more vessel-like tubes in culture; the Zagreb group reported “no direct angiogenic effect of BPC 157 on cell cultures”.11,15 The nitric-oxide link is also untidy. The Taiwanese and Turkish laboratories found effects that depend on nitric oxide, although part of the artery relaxation remained when it was blocked.12,13 In the Zagreb group’s own rat experiments, by contrast, the protective effects largely persisted when nitric oxide synthesis was blocked.19,20 These findings do not yet fit one causal story.

Steps 5 and 6: tissue and healing in animals

Injured rat muscle and tendon showed more blood vessels and stronger VEGF staining , blood flow recovered faster in rats with a blocked leg artery , and new tissue around sponges implanted in rats, and wounds in diabetic mice, organised their collagen earlier .15,11,9 The Zagreb reports of faster functional healing are discussed under the evidence below.

In detail Three weak links: what the chain does not show

The chain has three weak joints. No study measured the early steps and the healing outcome in the same animals, so the link between them is inferred. Nobody knows what concentration reaches a human tendon, so the cell concentrations cannot be translated. And several of the Zagreb group’s animal studies report the same benefit at a low and a high dose a thousand-fold apart.1,21 A real drug effect usually grows with dose up to a ceiling, so a flat response across that range weakens the causal inference.

What the evidence actually shows

Does it work?

Unknown in people. Rat studies mostly show faster healing, but most come from one group.

Most lab and animal studies come from one group in Zagreb

about 140 of 160

lab and animal papers have authors from one group in Zagreb

What was counted Roughly 160 primary lab and animal studies in PubMed, about 20 of them from outside Zagreb (our count, 20 October 2026) Source National Library of Medicine (2026)22 Evidence Animals

An independent tendon test found no clear gain in strength

32 rats

with repaired tendons. Strength and overall tissue scores were not clearly better; one collagen measure was.

Who took part Biçer 2026, Turkey: 32 rats in four groups of 8 (4 per group in each test), four weeks, assessors blinded Source Biçer et al. (2026)16 Evidence Animals

The one finished controlled trial in patients found no clear benefit

3.2 vs 1.6

points that a colitis score fell, with the peptide and with placebo. The gap could be chance.

Who took part PL 14736 phase 2: 53 people with mild-to-moderate ulcerative colitis, enema, randomised and double-blind; a 2005 conference abstract only Source FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 20261 Evidence Human trials

Four small reports on people had no comparison group

33 people

in all four reports together. None had a group of untreated people to compare with.

Who took part Lee 2021 (16 people), Lee 2024 (12), Lee 2025 (2) and Froum 2026 (3); no comparison group in any Sources Lee & Padgett (2021); Lee et al. (2024); Lee & Burgess (2025); Froum et al. (2026)23,24,25,26 Evidence Humans, limited

This evidence is not worthless. Across many rodent models of tendon, ligament, muscle and gut injury the direction of effect is consistent, and laboratories outside Zagreb (in the US, Taiwan and Turkey among others) have reported effects in the same direction.27,11,16,28 Promising animal data are a reason to run a good trial, not a substitute for one.

In detail Every study in one table, and where the evidence comes from

16 studies: 5 in humans, 6 in animals, 4 in cells, 1 reviews or other.

Studies discussed on this page
Study Species n Design Funding Research group What it found What it did not show
Staresinic et al. 2003 8 Rats not reported Animal experiment (controlled) Not disclosed Originating group After cutting the Achilles tendon in rats, daily BPC-157 improved load to failure, stiffness, a walking-function index and tissue appearance over 14 days compared with saline. Originating group; animal numbers and blinding not stated in the abstract; three doses a million-fold apart were tested but the abstract reports no dose–response; treatment started 30 minutes after injury.
U.S. Food and Drug Administration 2005 1 Humans 53 Phase II trial (controlled, blinded) Industry Mixed In a randomised, double-blind trial of an enema (PL 14736) in 53 people with mild-to-moderate ulcerative colitis, a disease-activity score fell by 3.2 points with BPC-157 and 1.6 with placebo; the difference was not statistically significant. Published only as a conference abstract; the FDA called the data inadequate (endpoint, entry criteria and statistics unclear). Part of the developer's own PL 14736 programme; never followed by a full paper.
Tkalcević et al. 2007 9 Mixed not reported Animal experiment (controlled) Industry Mixed PL 14736 (BPC-157) stimulated granulation tissue around implanted sponges in rats and in wounds of diabetic mice in a similar way to PDGF-BB, the growth factor in becaplermin gel, and was more active in organising collagen early; in a human gut-cell line it switched on EGR-1 faster than PDGF-BB. Run by the laboratory of the company developing PL 14736, whose staff also co-wrote papers with the Zagreb group, so not independent of the developer; animal numbers not stated in the abstract.
Klicek et al. 2008 20 Rats not reported Animal experiment (controlled) Not disclosed Originating group BPC-157 given by injection or in drinking water closed surgically created colon-to-skin fistulas in rats over 28 days; its effect persisted when nitric oxide production was blocked with L-NAME. Originating group; treatment started 30 minutes after the fistula was made, so it says nothing about established fistulas; the FDA noted no tissue histopathology data and no dose–response between the two doses tested.
Chang et al. 2011 14 Cells (lab) not reported Laboratory (cells) (controlled) Not disclosed Independent group Tendon pieces from rats grew out cells faster with BPC-157; the cells migrated and spread more, survived hydrogen-peroxide stress better and showed more activated FAK and paxillin. Cell division itself did not increase. Cells and tissue pieces in a dish from one species; one laboratory; no living animal and no clinical outcome.
Chang et al. 2014 18 Cells (lab) not reported Laboratory (cells) (controlled) Mixed Independent group BPC-157 increased growth hormone receptor levels in rat tendon fibroblasts in a dose- and time-dependent way; adding growth hormone then made the cells multiply more and activated JAK2 signalling. Cells in a dish; the same laboratory as the 2011 study; not repeated by another group; no animal or human test of the idea.
Hsieh et al. 2017 11 Mixed not reported Animal experiment (controlled) Not disclosed Independent group More blood-vessel growth in chick-egg membranes and in endothelial tube assays; faster blood-flow recovery and more vessels in ischaemic rat hind limbs; more VEGFR2 (but not more VEGF) in human endothelial cells, with VEGFR2–Akt–eNOS activation. Mixed cell, egg and rat experiments from one laboratory; animal numbers and blinding not stated in the abstract; not replicated independently.
Hsieh et al. 2020 12 Mixed not reported Laboratory (cells) (controlled) Academic Independent group BPC-157 widened isolated rat aorta rings in a concentration-dependent, mainly endothelium-dependent way that was reduced by the nitric oxide synthase inhibitor L-NAME; in endothelial cells it activated Src, caveolin-1 and eNOS. Isolated vessels and cells only; same Taiwanese laboratory; says nothing about blood pressure or healing in a living animal or person.
Xu et al. 2020 29 Mixed not reported Animal experiment (controlled) Not disclosed Independent group Across studies in mice, rats, rabbits and dogs, single injections and 28-day repeated injections (rats and dogs) caused no serious toxicity; standard genotoxicity tests were negative; no malformations in a rat embryo–fetal study. One laboratory; 28 days at most, intramuscular route only; histopathology data not published; the FDA re-analysis flagged clotting-time, liver and blood-fat changes; no carcinogenicity study.
Lee & Padgett 2021 23 Humans 16 Case series (uncontrolled) Not disclosed Independent group Of 16 people with various kinds of knee pain who had received knee-joint injections of BPC-157 (some with thymosin beta-4), 14 said by phone that their pain had improved. Retrospective phone survey, mostly 6–12 months after the injection; no comparison group, no validated pain scale, mixed diagnoses; one private clinic; funding not stated.
He et al. 2022 2 Mixed 372 Pharmacokinetic study (uncontrolled) Government Independent group In 366 rats and 6 dogs, BPC-157 disappeared from blood within minutes (half-life about 15 minutes in rats and 5 minutes in dogs after intravenous dosing); it was broken into smaller fragments and finally single amino acids. Animals only; intravenous and intramuscular routes only; says nothing about subcutaneous, oral or nasal use, or about people.
Lee et al. 2024 24 Humans 12 Open-label study (uncontrolled) Not disclosed Independent group Twelve women with interstitial cystitis that had not responded to pentosan polysulfate, an approved treatment, had BPC-157 injected into the bladder wall once; 10 reported complete symptom resolution and no adverse events were reported. No comparison group, no blinding, self-rated global response only; one private clinic using a compounded product; follow-up not clearly described.
Lee & Burgess 2025 25 Humans 2 Open-label study (uncontrolled) Not disclosed Independent group Two adults received intravenous BPC-157 on two consecutive days; blood tests and vital signs did not change and no side effects were reported. Two people, both of whom had used intravenous BPC-157 before; three days of follow-up; cannot detect anything but very common, immediate effects.
Biçer et al. 2026 16 Rats 32 Animal experiment (controlled, blinded) Academic Independent group In 32 rats with repaired Achilles tendons (8 per group), BPC-157 gave higher load to failure and better total tissue scores than control, but neither difference reached statistical significance; TB-500's did. One collagen measure (type I collagen staining) was significantly higher with BPC-157. The combination added nothing. Small, four-week study: each group's 8 tendons were split, 4 for strength testing and 4 for tissue analysis. Assessors were blinded and the authors declared no funding, but the study is too small to rule a modest effect in or out, and one positive result among many tissue measures is weak evidence.
Froum et al. 2026 26 Humans 3 Case series (uncontrolled) — Independent group Three dental patients with numbness after injury to a nerve in the lower jaw had weekly gum injections of a five-drug mixture that included BPC-157; feeling largely returned over about four weeks and no adverse events were reported. Three people, no comparison group, no standard nerve tests; BPC-157 was mixed with two other experimental peptides, a steroid and a local anaesthetic, and milder injuries of this nerve often recover by themselves. The authors say causality cannot be established. No funding declared.
Yildirim et al. 2026 13 Cells (lab) 12 Laboratory (cells) (uncontrolled) Academic Independent group In rings of chest artery left over from heart-bypass surgery in 12 men, BPC-157 relaxed the artery more as the concentration rose. The effect was much larger with the vessel lining intact and was weakened when nitric oxide production was blocked with L-NAME. Pieces of artery in a lab bath, from men with severe coronary artery disease; concentrations far above blood levels measured in rats; no rings given only the solvent over the same time; part of the relaxation remained with nitric oxide blocked. Says nothing about blood pressure or healing.
Where the evidence on BPC-157 comes from. We counted it on 20 October 2026.
LevelRoughly how muchWho produced itMain limitation
Cells and isolated tissueA minority of the roughly 160 primary laboratory and animal papersZagreb and others; most signalling work from one laboratory in Taiwan; one human-artery study from TurkeyConcentrations not linked to real exposure
Animal injury modelsMost of the roughly 160 primary papers (cells and animals together: about 140 from the Zagreb group, about 20 from elsewhere)Zagreb dominates; a few studies each from China, Taiwan and Turkey; single studies from South Korea and the USAMostly rats; treatment starts at or before injury; little direct repetition
Toxicology and pharmacokineticsTwo papersOne laboratory in Xi’an, China28 days at most; injected routes only
Humans, controlledTwo trials: phase 1 in 32 healthy men, phase 2 in 53 people with ulcerative colitisDeveloper of PL 14736Conference abstracts only; the phase 2 result was not statistically significant
Humans, uncontrolledFour reports, 33 peopleThree from Florida clinics with the same lead author; one from US dentistsNo comparison group; self-reported outcomes; one used a five-drug mixture
In detail Cell and animal studies, one by one

Cells and isolated tissue: mostly one independent laboratory

Four of the laboratory studies in the table come from one group at Chang Gung University: independent of Zagreb, but not of each other.14,18,11,12 They show that the molecule can change a pathway in a dish, not that it helps a damaged tendon in a person.

Other groups have since reported two of the same effects. The Xi’an laboratory saw more vessel-like tubes in cultured human endothelial cells.10,11 And in 2026 an Ankara team put rings of chest artery, left over from bypass surgery in 12 men, in a lab bath. BPC-157 relaxed the rings more as its concentration rose, mostly through the vessel lining and nitric oxide, as in the Taiwanese rat aorta.13,12 It is the first such test in pieces of human artery, but its limits are clear. The concentrations were far higher than blood levels measured in rats, the men had advanced heart disease, and no rings were given only the solvent over the same time. It shows an effect on artery tone in a dish, not on blood pressure or healing in a person.13

The originating group’s animal studies

Most of the literature is animal work by Predrag Sikirić, Sven Seiwerth and colleagues in Zagreb: by our count, about 140 primary experimental papers.22 The history page how one laboratory built the BPC-157 literature explains the count and why it matters.

Two studies show the typical design. In 2003 the group cut the Achilles tendon in rats and gave daily intraperitoneal BPC-157 at 10 µg/kg, 10 ng/kg or 10 pg/kg, or saline, starting 30 minutes after surgery. Treated tendons were stronger and stiffer, the rats walked better, and the defect closed over 14 days .8 In 2008 the group created colon-to-skin fistulas in rats, and BPC-157 by injection or in drinking water closed them .20 Similar results were reported for ligament, muscle, nerve and gut injuries.21,15,1

The FDA’s 2026 review looked closely at the group’s gut, liver and fistula studies, the ones relevant to ulcerative colitis, and made three criticisms.1 Low and high doses worked equally well, so no dose–response relationship was shown. Treatment started before, with or soon after the injury, so it is unknown whether BPC-157 helps once damage is established, which is when a person would use it. And without a known target, biological plausibility is hard to judge. The tendon and ligament studies above also started treatment 30 minutes after surgery, and the ligament study reported the same benefit at both of its doses.8,21 Their abstracts also do not say whether outcome assessors were blinded.

Independent animal studies

Groups outside Zagreb have tested BPC-157 in their own rodent models.22 As early as 1995, an industry laboratory at Parke-Davis in the US found that the peptide (under the name BPC-15) reduced chemically induced colon damage in rats in a dose-dependent way , one of the few reports with a dose–response.27 As in many Zagreb studies, treatment started at or before the moment of injury: here, one hour before.

A 2025 study from Ankara, with one author in common with the artery study, used a similar design. It used 24 rats in four groups of six, and gave BPC-157 at the start of a 45-minute block of blood flow to the legs. Two hours after blood flow returned, the liver, kidneys and lungs of the treated rats showed less damage and more antioxidant activity than those of rats with the same injury and no treatment .28 Treatment at the moment of injury and a two-hour follow-up say nothing about recovery from an established injury.

The first independent test of the flagship tendon claim came only in 2026. A Turkish team cut and then surgically repaired the Achilles tendons of 32 rats and gave BPC-157, TB-500, both, or nothing for four weeks. (The Zagreb studies left the cut tendon unrepaired, so this is a related model, not an exact repeat.) BPC-157 gave higher load to failure and better total tissue scores than control, but these differences were not statistically significant ; TB-500’s were, and the combination added nothing. One collagen measure, the staining of type I collagen, was significantly higher with BPC-157 .16 The assessors did not know which treatment each tendon had received, a safeguard the abstracts of the Zagreb tendon and ligament studies cited here do not report. But each group’s eight tendons were split, four for strength testing and four for tissue analysis, so the study could miss a modest effect, and a single positive result among many tissue measures is weak evidence.16 Its result fits a benefit smaller than the “full recovery” the Zagreb studies describe, or none.

In detail Toxicology, and how fast the body breaks it down

The only formal toxicology comes from the Fourth Military Medical University in Xi’an, China, which was developing BPC-157 for wounds, severe trauma and burns.29,2 Across mice, rats, rabbits and dogs, single and 28-day repeated intramuscular doses caused no serious toxicity; genotoxicity tests were negative, and a rat embryo–fetal study found no malformations .29 The FDA’s re-analysis of the same data flagged possible safety signals (see the risk profile below).1

The same laboratory studied 366 rats and 6 beagle dogs. Intact BPC-157 had a half-life of 15.2 min in rats and 5.3 min in dogs after intravenous dosing. Only part of an intramuscular dose reached the blood, and the peptide was degraded to fragments and then amino acids.2 The FDA found no animal or human data on how the body handles BPC-157 after subcutaneous, oral or nasal use. The only human blood measurements, after an enema, mostly found no peptide.1

In detail Studies in people, and the trials still running

Human evidence

The PL 14736 programme. PLIVA developed the peptide as an enema for inflammatory bowel disease. According to the FDA’s summary of conference abstracts, a placebo-controlled phase 1 study randomised 32 healthy men. Headache and flatulence were the commonest complaints, at similar rates with peptide and placebo, and the peptide was mostly undetectable in blood.1 In a randomised, double-blind phase 2 trial in 53 people with mild-to-moderate ulcerative colitis, a disease-activity score fell by 3.2 points with the peptide and 1.6 with placebo, and the confidence interval for the difference included zero .1 That trial appeared only as a 2005 conference abstract, which the FDA judged “inadequate to support the efficacy and safety” of BPC-157. No full report or later trial has been published since.

Four small uncontrolled reports. Three of them share one lead author, took place at private clinics in Florida, and used products from US compounding pharmacies.1

  • In a retrospective chart review of knee-joint injections (some combined with thymosin beta-4), 14 of 16 people reached by phone months later said their pain had improved .23
  • Twelve women with interstitial cystitis that had not responded to pentosan polysulfate, an approved treatment, had injections into the bladder wall; 10 rated their symptoms as fully resolved, and no adverse events were reported .24
  • In two adults given intravenous infusions on consecutive days, blood tests and vital signs did not change .25

The fourth report came from a group of US dentists in 2026. Three patients had numbness in the lip and chin after injury to a nerve in the lower jaw. Each had weekly injections into the gum, for four weeks, of a mixture of five drugs: BPC-157, TB-500, a third experimental peptide (ARA-290), the steroid dexamethasone and a local anaesthetic. Feeling largely returned, and no adverse events were reported . The authors themselves say that milder injuries of this nerve often recover on their own, and that the steroid and the anaesthetic given at the same time could also explain the recovery. With five drugs at once, no single one can be credited.26 One of the six authors lists the American Academy of Anti-Aging Medicine (A4M) as their affiliation. The authors declared no funding and no commercial or financial relationships that could be a conflict of interest.26

A 2026 systematic review, which searched the literature up to 1 June 2026, found the first three studies, 30 people in total, and rated the certainty of evidence as very low.17 The dental report was published after that search.26

Uncontrolled reports cannot show benefit, for structural reasons. Knee and bladder pain come and go on their own, and many nerve injuries slowly heal by themselves. People seek treatment when symptoms are worst, so many improve afterwards whatever is done (regression to the mean). An injection from a confident clinician produces a real placebo response, and asking people months later adds recall bias. Only a comparison group given a dummy treatment separates these effects from a drug effect.

Registered trials

As of 20 October 2026, ClinicalTrials.gov lists four studies: a 2015 phase 1 study of oral tablets in Mexico, status unknown, with no results;30 a randomised, placebo-controlled phase 2 trial of subcutaneous BPC-157 for acute hamstring strain in 120 people in China, recruiting, with primary completion expected in February 2027;31 a small randomised pilot after rotator-cuff surgery at a US university, not yet recruiting, whose record contradicts itself on the comparison group (saline injections in one place, no treatment in another) and on size (20 or 30 participants);32 and a completed single-arm study of an oral consumer product, run by its maker, with no results posted.33

In detail Where the evidence is genuinely promising, and what the gap costs

Two findings from the Taiwanese cell laboratory have since been reported by other groups, one of them in human artery tissue.10,13 Animal toxicology so far shows no genotoxicity and no acute toxicity at high doses.29 Independent reviewers in sports medicine describe the preclinical record as promising while stressing how little human data exist.5,34 Tendon and ligament injuries heal slowly and few medicines speed that healing, so a properly tested healing agent would be valuable.

The gap has a real cost. In public records the developer’s programme never went beyond a phase 2 trial that was not fully published, and two decades passed without a definitive trial. Into that gap came a grey market of unmonitored injections of products of unknown content.

What is genuinely unknown

What is still not known?

Whether it works in people, what longer use does, and what products contain.
Safety was tested for four weeks at most. Longer use has not been tested for safety. How many weeks of use the safety evidence covers, in animals and in people. One rat healing study gave it daily for up to 90 days, but it was not a safety study.

  • Longest safety (toxicity) study in animals: rats and dogs

    28 days

  • Longest use in the published human reports

    four weeks at most

  • Longest rat healing study (ligament)

    up to 90 days; not a safety study

  • Safety of longer use

    Not known: no safety studies in animals or people

Sources Xu et al. (2020); FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026; Froum et al. (2026); Cerovecki et al. (2010)29,1,26,21 Checked

In detail All eleven open questions, with their sources

As of 20 October 2026, these are specifically unknown:

  • Whether it works in people. No controlled human trial has been published in full.17
  • How it works. No receptor or primary target is established.1
  • Human pharmacokinetics. There are no data for subcutaneous, oral, nasal or transdermal use. After an enema it was mostly undetectable in blood.1
  • Dose–response. In the animal studies the FDA reviewed, low and high doses gave the same effect. One independent 1995 rat study did report a dose-dependent effect. There are no human dose–response data.1,27
  • Long-term safety. The longest repeat-dose toxicity study in animals lasted 28 days. In the published human studies use lasted at most four weeks, and most did not say how safety was monitored.29,1,26
  • Cancer risk. The FDA found no carcinogenicity study, and effects on existing tumours are untested.1
  • Reproduction. There is one rat embryo–fetal study, with no fertility, postnatal or human pregnancy data.1
  • Immune reactions. Neither the nominators nor the FDA found any study that formally tested immunogenicity.1
  • Interactions with any other medicine.
  • Whether the salt forms (free base, acetate, trifluoroacetate) behave alike.1,6
  • What products contain. A US sports drug-testing laboratory identified the peptide in confiscated vials,35 but we found no published survey of the content, impurities or sterility of products on the market.

Regulatory status

Is it legal?

It is approved nowhere and banned in sport. The 2026 US vote was only advice.
It is not an approved medicine anywhere. The July 2026 US vote did not change that. Status in the Netherlands, the EU and the US, and in sport, checked on 20 October 2026.
Netherlands and the EUUnited States
Approved as a medicine?No No EU or Dutch authorisation. EMA’s medicines data hold no record of it.36,37,38No Not FDA-approved.1
Legal to sell or supply as a medicine?No Dutch law forbids selling or supplying a medicine that has no marketing authorisation, with narrow exceptions.39No Pharmacies may not legally make it until the FDA accepts the advice and makes a rule adding it to the 503A list.40,1
Changed by the July 2026 US vote?No Nothing the FDA or its advisers decide changes the law here.39No On 23 July 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8–6, with one abstention, to recommend it for the 503A list. These numbers are as reported from the public meeting. It recommended six of the seven peptides it considered. The vote was only advice, and went against FDA staff’s own recommendation.41,42,43
Would a US listing make it an approved medicine?No It would change nothing in the EU or the Netherlands.39No It would allow pharmacy compounding on prescription in the US. It is not an approval and says nothing about efficacy.44,45,40
Allowed in sport?No Banned at all times since 1 January 2022.46,47No The same worldwide rule applies.47
In detail Status in each country, and in sport
Regulatory status by jurisdiction
Jurisdiction Status Note Checked
European Union Not authorised No authorised product, and no record in EMA's medicines data (checked 20 October 2026). 36,37
Netherlands Not authorised Not authorised; supplying an unauthorised medicine is prohibited by the Geneesmiddelenwet. 38,39
Germany Not authorised Not authorised; finished medicines need a licence under AMG § 21. 49,37,1
Belgium Not authorised Not authorised; the 1964 Medicines Act requires a national or EU licence, and none exists. 50,37,1
United Kingdom Not authorised Not authorised; supplying an unauthorised medicinal product is prohibited by the Human Medicines Regulations 2012. 51,1
United States Not authorised Not FDA-approved. The July 2026 advisory vote to recommend pharmacy compounding is non-binding; no rule has been made. 1,43,41,53,52
Sport (WADA) Prohibited in sport · S0, at all times Since Prohibited at all times under S0 since 1 January 2022; still named in the 2027 List. 46,47,48

All statuses were checked on 20 October 2026.

Sport (WADA)

BPC-157 has been named on the World Anti-Doping Agency’s Prohibited List since 1 January 2022, under S0 (non-approved substances), and is banned at all times.46,47 The 2027 List, in force from 1 January 2027, still names it and adds “peptides” in general to the S0 examples.48 (A 2025 review states that it is no longer listed; that is wrong.4) S0 covers substances with “no current approval by any governmental regulatory health authority for human therapeutic use”, so a US compounding listing, which is not an approval, would not by itself change that status.47

In detail The European Union, the Netherlands, Germany, Belgium and the United Kingdom

European Union and member states

No BPC-157 product has an EU marketing authorisation. EMA’s medicines data, which include refused and withdrawn applications, contain no record of it, and the European Pharmacopoeia has no monograph.36,37,1 The FDA found no approved product in any country.1

  • Netherlands. The CBG database lists no BPC-157 product.38 Under the Geneesmiddelenwet a substance is a medicine if it is meant for, or presented as suitable for, curing or preventing disease, wounds or pain, or changing body functions through a pharmacological effect (art. 1). Selling, supplying, stocking or importing a medicine without a marketing authorisation is prohibited, with narrow exceptions (art. 40).39
  • Germany. Finished medicines may be marketed only with a national licence or an EU authorisation (AMG § 21); BPC-157 has neither.49,37
  • Belgium. A medicine may be placed on the market only after a national or EU marketing authorisation has been granted (Medicines Act of 25 March 1964, art. 6 § 1). BPC-157 has no EU authorisation, and the FDA found no approved product anywhere.50,37,1

United Kingdom

Selling or supplying an unauthorised medicinal product is prohibited (Human Medicines Regulations 2012, regulation 46), and no BPC-157 product is authorised.51,1

In detail The United States, and the July 2026 vote point by point

BPC-157 is not FDA-approved, has no US Pharmacopeia monograph and is part of no approved drug. A pharmacy may therefore compound with it only once it is placed on the 503A bulks list through rulemaking.40,1 The FDA had earlier put BPC-157 in Category 2 of its interim policy, for substances that may present significant safety risks. When the nominators withdrew, it moved to a list of withdrawn substances; on the FDA’s 14 May 2026 list it is in no category.52,53

The FDA nevertheless evaluated BPC-157 on its own initiative, for ulcerative colitis only, and its staff concluded that it should not be listed: it is not well characterised, and effectiveness and safety are unsupported.1,43 What happened next is the most misreported fact about BPC-157:

  • On 23 July 2026 the FDA’s Pharmacy Compounding Advisory Committee (PCAC) voted 8–6 with one abstention to recommend BPC-157 for the 503A bulk drug substances list (count as reported from the public meeting; see below).41,42
  • The committee considered seven peptides over two days.41,43 As reported from the meeting, it recommended six: BPC-157, KPV, TB-500, MOTS-c, Semax and epitalon. Emideltide (DSIP) was not recommended.
  • The vote is advisory and non-binding, and it went against the FDA staff’s own recommendation.41,43
  • Legal compounding remains prohibited until the FDA formally adopts the recommendation and completes rulemaking.40
  • None of these is an approved medicine in the EU, the UK or the US (Semax is registered as a medicine in Russia). A 503A listing, if it ever happens, would allow pharmacy compounding on prescription in the US. It is not a marketing authorisation, says nothing about efficacy, and changes nothing in the EU or the Netherlands.44,45,1,54,36,40

Even a listing would not make compounded BPC-157 an FDA-checked product. The FDA reminded the committee that a compounded drug is not FDA-approved and need not follow good manufacturing practice (although insanitary conditions remain prohibited), and that compounders need not report its adverse events to the FDA. Unless the listing sets limits, the substance can be compounded for any use and route.44

The FDA documents confirm the date, the seven peptides, the voting questions and the staff recommendation. The voting questions asked about the free base and the acetate salt of BPC-157 separately.42 The FDA had not posted written minutes by 20 October 2026, so the vote counts and the six-of-seven outcome are as reported from the public meeting; we will check them against the minutes, including whether the two BPC-157 votes differed.41 By the same date the FDA had not proposed a rule to add BPC-157 to the list.55,40

Risk profile

What are the risks?

Its risks in people are unknown. Animal tests and unchecked products point to possible harms.
Several harms are possible. None has been studied properly in people. What lab and animal findings suggest, and what is known in people, as of 20 October 2026.
Possible harmShown in people?
Infection from germs or bacterial toxins in the productUnknown The product certificates the FDA reviewed did not report tests for them.1
An immune reaction, from mild to life-threateningUnknown The FDA says that, injected or sprayed into the nose, it may pose a significant risk. The FDA found no study that tested this.1
Changes in blood clottingUnknown Clotting times changed in 28-day tests in rats and in dogs, both from one lab.1
Changes in a liver enzyme and blood fatsUnknown Both rose in female rats; blood fats also rose in female dogs.1
Helping a hidden tumour growUnknown A worry based on cell and rat findings. It is untested.11,14,1
Darker skin and gumsUnknown Reported once to the FDA, after a product that mixed BPC-157 and TB-500. It does not show that BPC-157 was the cause.1

BPC-157 is prohibited in sport at all times,47 and methods to detect it in urine have been published.35

In detail What has been reported in people

The published human studies reported no serious adverse events, but the FDA notes they were short, small and said little about how safety was monitored.1 The 2026 dental report, published after the FDA review, reported no adverse events.26 The FDA’s adverse-event database held three reports up to 4 December 2025, all after injections: nine days of redness and swelling at the injection site (in someone also injecting thymosin); shortness of breath leading to an emergency visit; and diffuse darkening of the skin and gums after a week of a combined BPC-157 and TB-500 product labelled “for research purposes only”. The same reaction came back when the product was restarted, and there were no further reactions after the person stopped all peptides.1 None proves that BPC-157 was the cause. US compounding pharmacies do not have to report adverse events to the FDA, so the small number of reports says little about how often problems occur.44,1

In detail What the animal toxicology flags

The Chinese toxicology paper called BPC-157 well tolerated. The FDA’s re-analysis of the same data described “clinically relevant safety signals”:29,1

  • Clotting. A shortened clotting time (aPTT) in male rats and a prolonged one in male dogs. In humans a shortened aPTT is a known risk factor for clots, and a prolonged one can be a risk factor for bleeding.
  • Liver and blood fats. Rises in a liver enzyme (ALT), glucose and triglycerides in female rats after treatment stopped, and raised triglycerides in female dogs.
  • Kidney marker. Lower creatinine in dogs.

Each came from a single 28-day study, and longer studies would be needed to tell whether the signals are real.1

In detail Product quality and immune reactions

The most immediate risk may be the product itself. The certificates of analysis the FDA reviewed reported purity, but not specific impurities, clumps of peptide, or tests for bacterial endotoxin or microbial contamination. The FDA calls endotoxin testing critical for anything injected.1 Peptides can clump together during storage, and synthesis leaves near-copies of the chain; both present the repeated, unfamiliar patterns the immune system is built to notice. The FDA concluded that, injected or sprayed into the nose, BPC-157 “may pose a significant risk for immunogenicity”, possibly made worse by aggregation and impurities. Neither the nominators nor the FDA found a study that formally tested this. Consequences of an immune response range from antibodies that cause no symptoms to severe, even life-threatening, reactions.1 See product risk.

The plate shows six things that may be wrong with a vial from outside a pharmacy, from what is in it to what was never tested.

What may be wrong with a vial bought online

Key

  1. May not be what the label says The FDA warns that one name can cover different salt forms, or even a different active substance. A French lab found that products sold as TB-500 did not always match their description.
  2. The amount may differ from the label A 2026 study in Australia tested 3 products sold as retatrutide. They held from about half to almost twice the amount on the label. The TB-500 certificates the FDA saw did not check the amount.
  3. May hold near-copies and leftover chemicals Making a peptide can leave chains that are too short or slightly wrong, plus leftover solvents and other chemicals. Most certificates the FDA saw gave the purity but did not say which impurities were there.
  4. May not be tested for bacterial toxins (endotoxin) For anything injected, the FDA says this test is key. The certificates it saw for BPC-157 and TB-500 did not have it.
  5. May not be tested for germs For injections, the FDA says germ tests are key too. The certificates it saw for BPC-157, KPV and TB-500 showed no germ tests.
  6. Clumps may make immune reactions more likely Peptides can stick together into clumps. The FDA says clumps and impurities may raise the risk of an immune reaction, from harmless to life-threatening. No study has tested this for BPC-157, KPV or TB-500.
In words

The picture shows one small glass vial with a grey rubber stopper and some white powder at the bottom. It has no label. Six numbers show what may be wrong with a vial like this when it is bought online. Number 1, on the glass where a label would be: it may not be what the label says. The FDA warns that one name can cover different salt forms, or even a different active substance. A French lab found that products sold as TB-500 did not always match their description. Number 2, on the powder: the amount may differ from the label. A 2026 study in Australia tested 3 products sold as retatrutide. They held from about half to almost twice the amount on the label. The TB-500 certificates the FDA saw did not check the amount. Number 3, on the powder: making a peptide can leave chains that are too short or slightly wrong, plus leftover solvents and other chemicals. Most certificates the FDA saw gave the purity but did not say which impurities were there. Number 4, inside the vial: it may not have been tested for bacterial toxins, called endotoxin. For anything injected, the FDA says this test is key, and the certificates it saw for BPC-157 and TB-500 did not have it. Number 5, inside the vial: it may not have been tested for germs. For injections the FDA says germ tests are key too, and the certificates it saw for BPC-157, KPV and TB-500 showed no germ tests. Number 6, on the powder: peptides can stick together into clumps. The FDA says clumps and impurities may raise the risk of an immune reaction, from harmless to life-threatening. No study has tested this for BPC-157, KPV or TB-500. That is why number 6 has a different colour: it is a possible risk, not a proven one.

Based on: FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026[1]; FDA Briefing Document for KPV-Related Bulk Drug Substances (KPV (free base) and KPV acetate), Pharmacy Compounding Advisory Committee meeting, 23-24 July 2026; FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026[60]; Piatkowski et al. (2026); Delcourt et al. (2023)

AI-generated illustration (gpt-image-2.5-sunburst-2026-09-08, 21 October 2026) CC BY 4.0 Image details The picture contains no text; the numbers and labels are added by this site.

In detail Why an effect on cancer is theorised

The short animation shows why the vessel growth that may help healing is also the reason for the cancer worry.

Animation · 25 seconds New blood vessels help wounds heal, but tumours need them too

Your device asks for less motion, so this animation does not play. The picture shows the end result and the list explains every step.

  1. In cells and rats, BPC-157 raised signals for new vessels. So did thymosin beta-4, which TB-500 comes from.

    In cells In animals

  2. In injured rat tissue, new small blood vessels grew into the damaged area.

    In animals

  3. In many of those rat studies, the injured tissue healed faster.

    In animals

  4. Tumours need new blood vessels too. Without them, a tumour cannot grow beyond a tiny size.

    In humans

  5. Could these peptides feed a hidden tumour in people? This has never been tested.

    Hypothesised

In short: In cells and rats, BPC-157 and thymosin beta-4, the protein TB-500 comes from, helped new small blood vessels grow, and injured tissue often healed faster. Tumours also need new vessels to grow. Whether these peptides could help a hidden tumour grow in people has never been tested: it is a worry, not a finding.

Lines: solid = shown in people long dashes = shown in animals long dashes = shown in cells in the lab short dashes = an idea, not yet shown

Based on: Hsieh et al. (2017)11; Freeman et al. (2011)56; Brcic et al. (2009)15; Malinda et al. (1999)57; Staresinic et al. (2003)8; Hanahan & Weinberg (2011)58; Carmeliet & Jain (2011)59; FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 20261; FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 202660

The reasoning combines well-established cancer biology with findings about BPC-157 from cells and rats:

  1. Tumours need blood vessels. Beyond a very small size a tumour can grow only by recruiting new vessels, which it does by releasing signals, chiefly VEGF. Inducing angiogenesis is a recognised hallmark of cancer.58 VEGF acts mainly through VEGFR2, and medicines that block this pathway are used to slow some cancers.59
  2. BPC-157 pushes on that pathway. It increased VEGFR2 levels and signalling in human endothelial cells and increased vessel growth in ischaemic rat muscle .11
  3. Cancer cells crawl with repair machinery. FAK and paxillin let a fibroblast crawl into a wound. In many cancers FAK is over-active and helps tumour cells survive, migrate and invade; it is a target of experimental cancer drugs.61 BPC-157 increased FAK and paxillin activation in tendon fibroblasts .14
  4. More growth hormone receptors amplify growth signals. BPC-157 raised growth hormone receptor numbers in tendon cells ;18 whether it does so in other cells, including tumour cells, is untested.

So the worry is not that BPC-157 creates cancer: it was not genotoxic in standard tests.29 The worry is that something which helps vessels sprout and cells migrate could help an existing, perhaps undiagnosed, tumour grow or spread. Genotoxicity tests detect the DNA damage that starts a cancer; they cannot detect promotion of one that already exists. That needs long-term carcinogenicity studies and human follow-up. No carcinogenicity studies of BPC-157 in the regulatory sense have been published.1

There are honest counter-arguments. The originating group argues that BPC-157 “controls” angiogenesis rather than simply driving it, and reports anti-tumour effects in some models.62 An independent review found only one cancer-related study, a mouse model of cancer weight loss in which tumour volume did not differ significantly.4 We found no published study that shows tumour promotion. The risk is plausible but untested.

A precedent shows why the question matters. Becaplermin (Regranex), a growth-factor gel for diabetic foot ulcers authorised in the US (its EU authorisation ended in 2012), “promotes cellular proliferation and angiogenesis”.63,37 Its 2011 label carried a boxed warning about more cancer deaths in people using three or more tubes. The warning was removed in November 2018, when the label reported the signal in one of three post-marketing studies, but the label still warns about cancers and forbids use over a known tumour.64,63 Such signals only emerge, and are only resolved, with large human datasets. BPC-157 has none.

If someone is going to do this anyway

This section exists to reduce harm. It gives no doses, schedules or sourcing advice, and it is not a recommendation to use this compound.

How can someone lower the risk?

Check the vial first, bring a doctor in, and know when to stop.

If your product did not come from a pharmacy: check before you use it

These checks can show that something is wrong. None of them can show that a product is good or free of germs.65,66,67

Tick each box when you have checked it.

  • The seal and the vial are whole

    A broken cap or seal, or a cracked vial, can let germs in. Then do not use it.68,69,70

  • The label shows the name, amount, batch number and expiry date

    In the EU, a medicine must show all four, even on a small vial. If one is missing, or the date has passed, that is a warning sign. Take a photo of the label.71,68

  • For BPC-157

    Check which form the label names. BPC-157 is sold as a free base or an acetate salt. The FDA treats them as different substances.1

  • It looks right

    A liquid, or a powder after mixing, should be clear and colourless, with no bits. Is it cloudy, has it changed colour, or do you see bits? Then do not use it.72,73

  • A lab report proves little if:

    • its batch number is not the one on your vial;
    • it does not name the lab, or has no date or signature;
    • it shows only purity (HPLC), with no test of what it is, such as mass spectrometry;
    • it has no test for germs (sterility) or for toxins from germs (endotoxin).

    Even a full report covers only one sample. A report from the seller comes from someone who gains if it looks good. It cannot show that your vial is clean.74,75,1,60,76

    What a certificate of analysis shows, and what it does not

  • It was kept as the label says

    Heat, freezing and sunlight can damage a peptide. Did it arrive warm, or was it frozen? Then do not use it. Often nobody can tell you how it was kept on the way. If you cannot know, you cannot rule out damage. When in doubt, throw it out.73,77,78,70

    When to throw a vial away

  • Clean steps, and a new sterile needle and syringe every time

    Wash your hands and wipe the rubber top with alcohol. Never share a needle, a syringe or a vial.70,79,77

    Sterile technique, step by step

  • Keep the vial, its label and any papers

    Keep them, even when the vial is empty, until you know you feel well. If you need a doctor, bring them. A lab can test what was inside.80,81

    If something goes wrong

  • Tell a doctor, and agree which checks fit you

    A doctor can help you choose blood tests that fit what you use. In the Netherlands, your doctor must keep what you say private.82,83,84

    Which checks matter, and whyTalking to your doctor

  • Know the warning signs before you start

    Spreading redness, fever, a swollen face or hard breathing need help fast. If it is severe, call your local emergency number.85,86,87

    All warning signs, and how fast to act

Talk to a doctor first

A doctor can check for the conditions where the theoretical risks matter most: cancer, pregnancy and clotting problems. A doctor can also make sure the injury itself is properly diagnosed. A torn tendon or ligament may need a scan or surgery within weeks. Using a peptide instead of a diagnosis can delay care that works. See talking to your doctor.

Sources 1, 11

Stop-now warning signs

Call your local emergency number now

  • Confusion or slurred speech, very fast breathing, or pale, blue or blotchy skin, often with fever or shivering These can be signs of sepsis: the body's reaction to an infection has started to damage its own organs.
  • Fainting and not waking up within a minute, or fainting with chest pain, a racing heart or a fit This can be a dangerous heart rhythm or a severe allergic reaction.
  • Pain at the injection spot that is much worse than it looks, or dark, purple or grey patches or blisters there This can be a rare, fast-spreading infection of the deep layers under the skin (necrotising fasciitis).
  • Swelling of the lips, tongue or throat, trouble breathing or swallowing, wheezing, a hoarse voice, or feeling faint, soon after an injection This can be a severe allergic reaction (anaphylaxis), which is life-threatening and gets worse very quickly.
  • Pain, pressure or tightness in the chest, or pain that spreads to the arm, neck, jaw or back This can be a heart attack, which needs treatment in hospital straight away.
  • Sudden, severe shortness of breath: gasping, or not able to finish a sentence This can be a serious problem with the heart, the lungs or an allergic reaction.
  • A racing, pounding or irregular heartbeat that does not settle, or that comes with chest pain, breathlessness or fainting This can be a dangerous heart rhythm.
  • A sudden, severe headache with blurred vision, chest pain, confusion or vomiting Blood pressure may be dangerously high, which can damage the brain, heart, kidneys and eyes.
  • An erection that lasts more than 3 hours, or a painful erection that will not go down Blood trapped in the penis can damage it for good if it is not treated quickly.
  • Shaking, sweating or sudden hunger that turns into confusion or drowsiness Very low blood sugar can cause a fit or loss of consciousness; take something sugary if you can still swallow safely.
  • Severe, constant pain in the upper belly that spreads to the back, often with vomiting This can be an inflamed pancreas (pancreatitis), a known risk of GLP-1 medicines such as semaglutide and tirzepatide.
  • Sudden weakness or numbness on one side, a drooping face, or slurred or confused speech These are signs of a stroke, which needs treatment in hospital straight away, even if the signs pass.
  • A headache that starts suddenly and is extremely painful, or a headache with a stiff neck, confusion or a fit This can be a stroke or another emergency in the brain.
  • Sudden loss of sight in one or both eyes This can be a stroke or damage to the nerve of the eye, and sight can be lost for good.
  • A fit (seizure): jerking movements, or suddenly not responding A fit can be caused by very low blood sugar or a problem in the brain, and needs checks straight away.

Get medical help today

  • Fever, shivering or feeling very ill in the days after an injection Germs from the needle, the skin or the product may have reached your blood. If you also have a fast heartbeat or fast breathing, call your local emergency number.
  • Redness, heat, swelling or pain around the injection spot that keeps growing or getting worse This can be a skin infection (cellulitis), which needs antibiotics before it spreads.
  • Red lines that run from the injection spot towards the armpit or groin The infection may be spreading along the lymph vessels, and from there into the blood. If you also have a fever with a fast heartbeat or fast breathing, call your local emergency number.
  • A painful, warm lump that fills with pus This is probably an abscess: it often needs draining by a doctor, so do not squeeze it.
  • You were pricked by a needle that someone else had used Blood on a used needle can pass on HIV and hepatitis B or C, and preventive treatment works best within hours.
  • Vomiting so often that you cannot keep fluids down, or passing very little urine Losing too much fluid can damage the kidneys.
  • Yellow skin, or yellow whites of the eyes This can be a sign of a liver problem, gallstones or an inflamed pancreas.
  • Dark, red or cola-coloured urine together with muscle pain, tenderness or weakness Damaged muscle can release a protein that harms the kidneys (rhabdomyolysis).

Stop and contact a doctor

  • You fainted, but woke up quickly and now feel well Fainting is often harmless, but a doctor should check the cause.
  • A new mole, or a mole that changes size, shape or colour, itches or bleeds A changing mole can be skin cancer, and tanning peptides such as melanotan II have been linked to new and changing moles in case reports.
  • A lump at an injection spot that does not go away, or keeps growing A doctor should check whether it is an abscess, a reaction to the product or something else.
  • An itchy, raised rash, or puffy eyes or lips, while breathing stays normal Your body may be reacting to the product, and using it again can bring the reaction back.
  • Palpitations that keep coming back, even if they pass and you then feel well A doctor can check whether your heart rhythm is normal.
In detail What you cannot know about the product

A vial labelled BPC-157 may hold a different salt, or more or less peptide than the label says. It may also hold near-copies of the chain, solvents or bacterial toxins. No regulator has checked it (see product risk). If you inject anything, follow sterile technique. A contaminated product or needle can cause an infection.

In detail Checks that make sense, and why

A doctor can help you choose which of these fit you:

  • Cancer screening due for your age, and any unexplained lump, bleeding or weight loss checked first, because of the theoretical effect on blood-vessel growth.
  • Liver enzymes and blood fats, because both rose in female rats, and blood fats also rose in female dogs.
  • Clotting tests, especially if you take a blood thinner or have had a clot, because clotting times changed in rats and dogs.
  • Kidney tests, telling the doctor you use BPC-157, because creatinine, the standard kidney marker, fell in dogs. If it does the same in people, a low value could make the kidneys look healthier than they are.
In detail Interactions, and who should not use it at all

Plausible interactions (none has been studied)

  • Blood thinners and antiplatelet medicines, because of the clotting changes in animals.
  • Medicines that lower blood pressure or act through nitric oxide (such as nitrates or sildenafil), because BPC-157 relaxed isolated rat and human arteries through nitric oxide.12,13
  • Cancer medicines that block blood-vessel growth, because BPC-157 pushes the same pathway the other way.
  • Combination products with other peptides, such as TB-500 blends, which add a second unknown, make any reaction impossible to attribute, and gave no extra benefit in rats.16,1

Who should not use it at all

  • Anyone pregnant, breastfeeding or trying to conceive: there are no human data, only one rat embryo–fetal study, and new vessel growth is central to pregnancy.
  • Anyone with cancer, a history of cancer or an undiagnosed lump, because of the angiogenesis and FAK mechanisms above.
  • Children and teenagers, whose tissues are still growing and for whom there are no data.
  • Anyone with a clotting disorder or on anticoagulants, because of the animal clotting signals.
  • Athletes subject to anti-doping rules, because it is prohibited at all times.

Sources

Every claim on this page links to one of these sources. Scholarly sources link to their DOI; regulatory sources to the regulator's own page.

In detail All 87 sources, numbered as in the text
  1. U.S. Food and Drug Administration (2026). FDA Briefing Document for BPC-157-Related Bulk Drug Substances (BPC-157 (free base) and BPC-157 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov — accessed 20 October 2026 ↩
  2. He L, Feng D, Guo H, Zhou Y, Li Z, et al. (2022). Pharmacokinetics, distribution, metabolism, and excretion of body-protective compound 157, a potential drug for treating various wounds, in rats and dogs. Frontiers in Pharmacology 13:1026182. Research article doi:10.3389/fphar.2022.1026182 ↩
  3. Sikirić P, Petek M, Rucman R, Seiwerth S, Grabarević Z, Rotkvić I, Turković B, Jagić V, Mildner B, Duvnjak M, et al. (1993). A new gastric juice peptide, BPC. An overview of the stomach-stress-organoprotection hypothesis and beneficial effects of BPC. Journal of Physiology, Paris 87:313-327. Review doi:10.1016/0928-4257(93)90038-u ↩
  4. Józwiak M, Bauer M, Kamysz W, Kleczkowska P (2025). Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel) 18:185. Review doi:10.3390/ph18020185 ↩
  5. Vasireddi N, Hahamyan H, Salata MJ, Karns M, Calcei JG, et al. (2025). Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal 21:485-495. Review doi:10.1177/15563316251355551 ↩
  6. National Center for Biotechnology Information (2026). PubChem Compound Summary for CID 9941957, BPC-157. PubChem. Dataset pubchem.ncbi.nlm.nih.gov — accessed 20 October 2026 ↩
  7. EMBL-EBI (2026). ChEMBL compound report card: CHEMBL4297358 (BPC-157). ChEMBL. Dataset ebi.ac.uk — accessed 20 October 2026 ↩
  8. Staresinic M, Sebecic B, Patrlj L, Jadrijevic S, Suknaic S, et al. (2003). Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research 21:976-983. Research article doi:10.1016/S0736-0266(03)00110-4 ↩
  9. Tkalcević VI, Cuzić S, Brajsa K, Mildner B, Bokulić A, et al. (2007). Enhancement by PL 14736 of granulation and collagen organization in healing wounds and the potential role of egr-1 expression. European Journal of Pharmacology 570:212-221. Research article doi:10.1016/j.ejphar.2007.05.072 ↩
  10. Zhang J, Liu M, Ou H, Wang Z, He L, et al. (2026). BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1. Cell Communication and Signaling 24. Research article doi:10.1186/s12964-026-02694-6 ↩
  11. Hsieh MJ, Liu HT, Wang CN, Huang HY, Lin Y, et al. (2017). Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. Journal of Molecular Medicine 95:323-333. Research article doi:10.1007/s00109-016-1488-y ↩
  12. Hsieh MJ, Lee CH, Chueh HY, Chang GJ, Huang HY, Lin Y, Pang JS (2020). Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Scientific Reports 10:17078. Research article doi:10.1038/s41598-020-74022-y ↩
  13. Yildirim AK, Dastan AO, Demeli Ertus M, Ensarioglu M, Karabacak K, Pehlivanoglu B (2026). Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. Journal of Clinical Medicine 15:3488. Research article doi:10.3390/jcm15093488 ↩
  14. Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. Journal of Applied Physiology 110:774-780. Research article doi:10.1152/japplphysiol.00945.2010 ↩
  15. Brcic L, Brcic I, Staresinic M, Novinscak T, Sikiric P, Seiwerth S (2009). Modulatory effect of gastric pentadecapeptide BPC 157 on angiogenesis in muscle and tendon healing. Journal of Physiology and Pharmacology 60 Suppl 7:191-196. Research article PMID 20388964 ↩
  16. Biçer O, Adanir O, Güleryüz Y, Balci EC, Dinçel YM, et al. (2026). Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint Diseases and Related Surgery 37:822-837. Research article doi:10.52312/jdrs.2026.2951 ↩
  17. Poolton JT, Minett J, Kazmi A (2026). Human evidence for BPC-157 in orthopaedic and regenerative medicine: a systematic review of efficacy and safety. Acta Orthopaedica Belgica 92. Review doi:10.52628/92.3.15837 ↩
  18. Chang CH, Tsai WC, Hsu YH, Pang JH (2014). Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts. Molecules 19:19066-19077. Research article doi:10.3390/molecules191119066 ↩
  19. Sikirić P, Seiwerth S, Grabarević Z, Rucman R, Petek M, et al. (1997). The influence of a novel pentadecapeptide, BPC 157, on N(G)-nitro-L-arginine methylester and L-arginine effects on stomach mucosa integrity and blood pressure. European Journal of Pharmacology 332:23-33. Research article doi:10.1016/s0014-2999(97)01033-9 ↩
  20. Klicek R, Sever M, Radic B, Drmic D, Kocman I, et al. (2008). Pentadecapeptide BPC 157, in clinical trials as a therapy for inflammatory bowel disease (PL14736), is effective in the healing of colocutaneous fistulas in rats: role of the nitric oxide-system. Journal of Pharmacological Sciences 108:7-17. Research article doi:10.1254/jphs.fp0072161 ↩
  21. Cerovecki T, Bojanic I, Brcic L, Radic B, Vukoja I, Seiwerth S, Sikiric P (2010). Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. Journal of Orthopaedic Research 28:1155-1161. Research article doi:10.1002/jor.21107 ↩
  22. National Library of Medicine (2026). PubMed search, 20 October 2026: ("BPC 157"[tiab] OR "BPC-157"[tiab] OR "BPC157"[tiab] OR "PL 14736"[tiab] OR "PL-14736"[tiab] OR "bepecin"[tiab] OR "BPC 157"[nm]) — 235 records, 175 with Sikiric P as author. PubMed. Dataset pubmed.ncbi.nlm.nih.gov — accessed 20 October 2026 ↩
  23. Lee E, Padgett B (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine 27:8-13. Research article PMID 34324435 ↩
  24. Lee E, Walker C, Ayadi B (2024). Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study. Alternative Therapies in Health and Medicine 30:12-17. Research article PMID 39325560 ↩
  25. Lee E, Burgess K (2025). Safety of Intravenous Infusion of BPC157 in Humans: A Pilot Study. Alternative Therapies in Health and Medicine 31:20-24. Research article PMID 40131143 ↩
  26. Froum S, Estrin N, Pico G, Yakubov M, Ahmad P, et al. (2026). Case Report: Regenerative peptides for Inferior alveolar nerve injury: a narrative review with hypothesis-generating three clinical cases. Frontiers in Oral Health 7:1907109. Research article doi:10.3389/froh.2026.1907109 ↩
  27. Veljaca M, Lesch CA, Pllana R, Sanchez B, Chan K, Guglietta A (1995). BPC-15 reduces trinitrobenzene sulfonic acid-induced colonic damage in rats. Journal of Pharmacology and Experimental Therapeutics 272:417-422. Research article PMID 7815358 ↩
  28. Demirtaş H, Özer A, Yıldırım AK, Dursun AD, Sezen ŞC, Arslan M (2025). Protective Effects of BPC 157 on Liver, Kidney, and Lung Distant Organ Damage in Rats with Experimental Lower-Extremity Ischemia-Reperfusion Injury. Medicina (Kaunas) 61:291. Research article doi:10.3390/medicina61020291 ↩
  29. Xu C, Sun L, Ren F, Huang P, Tian Z, et al. (2020). Preclinical safety evaluation of body protective compound-157, a potential drug for treating various wounds. Regulatory Toxicology and Pharmacology 114:104665. Research article doi:10.1016/j.yrtph.2020.104665 ↩
  30. ClinicalTrials.gov (2015). NCT02637284 — Phase I, pilot study in healthy volunteers, to assess the safety and pharmacokinetics of PCO-02, which active ingredient is BPC-157. Trial registration clinicaltrials.gov — accessed 20 October 2026 ↩
  31. ClinicalTrials.gov (2026). NCT07437547 — A randomized, double-blind, placebo-controlled phase 2 trial of pentadecapeptide BPC 157 for accelerated repair of acute grade II hamstring strain confirmed by MRI. Trial registration clinicaltrials.gov — accessed 20 October 2026 ↩
  32. ClinicalTrials.gov (2026). NCT07803250 — Impact of BPC-157 on recovery from rotator cuff repair surgery. Trial registration clinicaltrials.gov — accessed 20 October 2026 ↩
  33. ClinicalTrials.gov (2025). NCT07752381 — A clinical trial to evaluate the effects of peptide gummies on markers of inflammation, physical performance, and recovery. Trial registration clinicaltrials.gov — accessed 20 October 2026 ↩
  34. McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM (2025). Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current Reviews in Musculoskeletal Medicine 18:611-619. Review doi:10.1007/s12178-025-09990-7 ↩
  35. Cox HD, Miller GD, Eichner D (2017). Detection and in vitro metabolism of the confiscated peptides BPC 157 and MGF R23H. Drug Testing and Analysis 9:1490-1498. Research article doi:10.1002/dta.2152 ↩
  36. European Medicines Agency (2026). Medicines (search of centrally authorised medicines and EPARs). Regulator ema.europa.eu — accessed 20 October 2026 ↩
  37. European Medicines Agency (2026). Medicines data download (JSON report of all EPARs: authorised, refused, withdrawn and suspended medicines). Dataset ema.europa.eu — accessed 20 October 2026 ↩
  38. College ter Beoordeling van Geneesmiddelen (CBG-MEB) (2026). Geneesmiddeleninformatiebank (database of medicines authorised in the Netherlands). Regulator geneesmiddeleninformatiebank.nl — accessed 20 October 2026 ↩
  39. Staten-Generaal / Koninkrijk der Nederlanden (2007). Geneesmiddelenwet (BWBR0021505). wetten.overheid.nl. Law wetten.overheid.nl — accessed 20 October 2026 ↩
  40. U.S. Food and Drug Administration (2026). Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act. Regulator fda.gov — accessed 20 October 2026 ↩
  41. U.S. Food and Drug Administration (2026). July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Regulator fda.gov — accessed 20 October 2026 ↩
  42. U.S. Food and Drug Administration (2026). Questions, Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov — accessed 20 October 2026 ↩
  43. U.S. Food and Drug Administration (2026). FDA Briefing Document Introduction, Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov — accessed 20 October 2026 ↩
  44. U.S. Food and Drug Administration (2026). FDA Presentations, Pharmacy Compounding Advisory Committee meeting, 23 July 2026. Regulator fda.gov — accessed 20 October 2026 ↩
  45. Legal Information Institute, Cornell Law School (text of the United States Code) (2026). 21 U.S. Code § 353a – Pharmacy compounding (FD&C Act § 503A). United States Code. Law law.cornell.edu — accessed 22 October 2026 ↩
  46. World Anti-Doping Agency (2021). Summary of Major Modifications and Explanatory Notes, 2022 Prohibited List. Regulator wada-ama.org — accessed 20 October 2026 ↩
  47. World Anti-Doping Agency (2025). World Anti-Doping Code International Standard: Prohibited List 2026. Regulator wada-ama.org — accessed 20 October 2026 ↩
  48. World Anti-Doping Agency (2026). World Anti-Doping Code International Standard: Prohibited List 2027 (in effect 1 January 2027). Regulator wada-ama.org — accessed 20 October 2026 ↩
  49. Bundesministerium der Justiz (2026). Arzneimittelgesetz (AMG), § 21 Zulassungspflicht. gesetze-im-internet.de. Law gesetze-im-internet.de — accessed 20 October 2026 ↩
  50. Belgische Staat / État belge (1964). Wet van 25 maart 1964 op de geneesmiddelen voor menselijk gebruik, artikel 6 § 1 (vergunning voor het in de handel brengen vereist). ejustice.just.fgov.be. Law ejustice.just.fgov.be — accessed 20 October 2026 ↩
  51. UK Parliament (2012). The Human Medicines Regulations 2012 (SI 2012/1916), regulation 46: Requirement for authorisation. legislation.gov.uk. Law legislation.gov.uk — accessed 20 October 2026 ↩
  52. U.S. Food and Drug Administration (2026). Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Regulator fda.gov — accessed 20 October 2026 ↩
  53. U.S. Food and Drug Administration (2026). Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act (categories 1–3), updated 14 May 2026. Regulator fda.gov — accessed 20 October 2026 ↩
  54. U.S. Food and Drug Administration (2026). FDA Briefing Document for Semax-Related Bulk Drug Substances (Semax (free base) and Semax acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov — accessed 22 October 2026 ↩
  55. Office of the Federal Register (2026). Federal Register document search, 20 October 2026: "bulk drug substances", published from 24 July 2026 — no proposed or final rule on the 503A bulks list. Federal Register. Dataset federalregister.gov — accessed 20 October 2026 ↩
  56. Freeman KW, Bowman BR, Zetter BR (2011). Regenerative protein thymosin beta-4 is a novel regulator of purinergic signaling. FASEB Journal 25:907-915. Research article doi:10.1096/fj.10-169417 ↩
  57. Malinda KM, Sidhu GS, Mani H, Banaudha K, Maheshwari RK, et al. (1999). Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology 113:364-368. Research article doi:10.1046/j.1523-1747.1999.00708.x ↩
  58. Hanahan D, Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell 144:646-674. Review doi:10.1016/j.cell.2011.02.013 ↩
  59. Carmeliet P, Jain RK (2011). Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298-307. Review doi:10.1038/nature10144 ↩
  60. U.S. Food and Drug Administration (2026). FDA Briefing Document for TB-500-Related Bulk Drug Substances (TB-500 (free base) and TB-500 acetate), Pharmacy Compounding Advisory Committee meeting, 23–24 July 2026. Regulator fda.gov — accessed 20 October 2026 ↩
  61. Sulzmaier FJ, Jean C, Schlaepfer DD (2014). FAK in cancer: mechanistic findings and clinical applications. Nature Reviews Cancer 14:598-610. Review doi:10.1038/nrc3792 ↩
  62. Sikiric P, Seiwerth S, Skrtic A, Staresinic M, Strbe S, et al. (2025). BPC 157 Therapy: Targeting Angiogenesis and Nitric Oxide's Cytotoxic and Damaging Actions, but Maintaining, Promoting, or Recovering Their Essential Protective Functions. Comment on Józwiak et al. Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals 2025, 18, 185. Pharmaceuticals (Basel) 18. Research article doi:10.3390/ph18101450 ↩
  63. U.S. Food and Drug Administration (2018). REGRANEX (becaplermin) Gel — Prescribing Information (2018): boxed warning on cancer mortality removed 11/2018; malignancy warning retained. Drugs@FDA. Official product information accessdata.fda.gov — accessed 20 October 2026 ↩
  64. U.S. Food and Drug Administration (2011). REGRANEX (becaplermin) Gel 0.01% — Prescribing Information (2011), including boxed warning on increased rate of mortality secondary to malignancy. Drugs@FDA. Official product information accessdata.fda.gov — accessed 20 October 2026 ↩
  65. Inspectie Gezondheidszorg en Jeugd (IGJ) (2026). Online medicijnen. Regulator igj.nl — accessed 22 October 2026 ↩
  66. Ashraf AR, Mackey TK, Vida RG, Kulcsár G, Schmidt J, Balázs O, Domián BM, Li J, Csákó I, Fittler A (2024). Multifactor Quality and Safety Analysis of Semaglutide Products Sold by Online Sellers Without a Prescription: Market Surveillance, Content Analysis, and Product Purchase Evaluation Study. Journal of Medical Internet Research 26:e65440. Research article doi:10.2196/65440 ↩
  67. Smith RM, Schaefer MK, Kainer MA, Wise M, Finks J, et al. (2013). Fungal infections associated with contaminated methylprednisolone injections. The New England Journal of Medicine 369:1598-1609. Research article doi:10.1056/NEJMoa1213978 ↩
  68. U.S. Food and Drug Administration (2020). BeSafeRx: Considering an Online Pharmacy?. Regulator fda.gov — accessed 22 October 2026 ↩
  69. Hospira, Inc. / DailyMed (National Library of Medicine) (2026). Sterile Water for Injection, USP: prescribing information. Official product information dailymed.nlm.nih.gov — accessed 20 October 2026 ↩
  70. World Health Organization (2010). WHO best practices for injections and related procedures toolkit (WHO/EHT/10.02). World Health Organization, Geneva. Report who.int — accessed 20 October 2026 ↩
  71. European Parliament and Council of the European Union (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use (consolidated text). Official Journal of the European Communities, L 311. Law eur-lex.europa.eu — accessed 20 October 2026 ↩
  72. U.S. Food and Drug Administration / DailyMed (National Library of Medicine) (2026). EGRIFTA SV (tesamorelin for injection): prescribing information and instructions for use. Official product information dailymed.nlm.nih.gov — accessed 20 October 2026 ↩
  73. European Medicines Agency (2026). Wegovy (semaglutide): EPAR — overview and product information. Official product information ema.europa.eu — accessed 20 October 2026 ↩
  74. European Medicines Agency (ICH) (2000). ICH Q7 Good manufacturing practice for active pharmaceutical ingredients (CPMP/ICH/4106/00). European Medicines Agency, scientific guideline. Regulator ema.europa.eu — accessed 22 October 2026 ↩
  75. European Medicines Agency, CHMP and CVMP (2025). Guideline on the Development and Manufacture of Synthetic Peptides (EMA/CHMP/CVMP/QWP/367182/2025). European Medicines Agency. Regulator ema.europa.eu — accessed 22 October 2026 ↩
  76. Janvier S, Cheyns K, Canfyn M, Goscinny S, De Spiegeleer B, Vanhee C, Deconinck E (2018). Impurity profiling of the most frequently encountered falsified polypeptide drugs on the Belgian market. Talanta 188:795-807. Research article doi:10.1016/j.talanta.2018.06.023 ↩
  77. U.S. Food and Drug Administration (2026). FDA's concerns with unapproved GLP-1 drugs used for weight loss. Regulator fda.gov — accessed 20 October 2026 ↩
  78. Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS (2010). Stability of protein pharmaceuticals: an update. Pharmaceutical Research 27:544-575. Review doi:10.1007/s11095-009-0045-6 ↩
  79. Centers for Disease Control and Prevention (2024). Preventing Unsafe Injection Practices. Regulator cdc.gov — accessed 20 October 2026 ↩
  80. NHS (2025). Poisoning. Web page nhs.uk — accessed 22 October 2026 ↩
  81. Antonacci G, Bortignon E, Bolognesi M, Piano SS, Cadore A, Camuffo L, Venturini F, Faoro S, Favretto D, Romano A, Mengato D (2026). Hypoglycaemic coma induced by a falsified semaglutide product: a case report. European Journal of Hospital Pharmacy 33:486-489. Research article doi:10.1136/ejhpharm-2025-004656 ↩
  82. Thuisarts.nl (Nederlands Huisartsen Genootschap, NHG) (2024). Ik ga naar de huisarts: wat kan ik van tevoren doen en verwachten?. Web page thuisarts.nl — accessed 22 October 2026 ↩
  83. Department of Health, Victoria (Australia), Chief Health Officer (2026). Toxicity linked to unapproved peptide product labelled Retatrutide (health alert). Regulator health.vic.gov.au — accessed 22 October 2026 ↩
  84. KNMG (Royal Dutch Medical Association) (2024). Medisch beroepsgeheim: wat en waarom. Web page knmg.nl — accessed 20 October 2026 ↩
  85. NHS (England) (2024). Cellulitis. Web page nhs.uk — accessed 20 October 2026 ↩
  86. NHS (England) (2026). Sepsis. Web page nhs.uk — accessed 20 October 2026 ↩
  87. NHS (England) (2023). Anaphylaxis. Web page nhs.uk — accessed 20 October 2026 ↩